Towards the end of December, without conducting any outreach to industry groups or consumer organizations, the Federal Trade Commission issued a new guidance document, Health Products Compliance Guidance. The new guidance is remarkable for many reasons, particularly for its frequently aggressive stances that outstrip established law in the field. For instance, the FTC now purports to require randomized, controlled, human clinical trials as the default substantiation for any health-related claim.
Learn more about the guidance and its implications for companies making health-related advertising claims in Lathrop GPM’s client alert.
The information contained in this post is provided to alert you to legal developments and should not be considered legal advice. It is not intended to and does not create an attorney-client relationship. Specific questions about how this information affects your particular situation should be addressed to one of the individuals listed. No representations or warranties are made with respect to this information, including, without limitation, as to its completeness, timeliness, or accuracy, and Lathrop GPM shall not be liable for any decision made in connection with the information. The choice of a lawyer is an important decision and should not be based solely on advertisements.
About this Publication
The Franchise Memorandum is a collection of postings on summaries of recent legal developments of interest to franchisors brought to you by Lathrop GPM LLP.
To subscribe to monthly emails for The Franchise Memorandum, please click here.
RSS Feed